Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline

Pharmacological Treatment of Parkinson Disease

(2014) Barbara S. Connolly et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The current and projected economic burden of Parkinson's disease in the United States

(2013) Stacey L. Kowal et al.   MOVEMENT DISORDERS

Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease

(2012) Jens P Reese et al.   EXPERT OPINION ON PHARMACOTHERAPY

Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study

(2012) Francesc Valldeoriola et al.   JOURNAL OF MEDICAL ECONOMICS

Prediction Model of Parkinson's Disease Based on Antiparkinsonian Drug Claims

(2011) F. Moisan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease

(2011) Rebecca Stowe et al.   MOVEMENT DISORDERS

The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset

(2011) Leslie J. Findley et al.   JOURNAL OF MEDICAL ECONOMICS

Trends in resource utilization for Parkinson's disease in Germany

(2010) Yaroslav Winter et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Costs of Parkinson’s Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study

(2010) Yaroslav Winter et al.   Neurodegenerative Diseases

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

(2008) C. Warren Olanow et al.   MOVEMENT DISORDERS